drugset / Trial / NCT06604065

Essential Amino Acids and Parkinsons Disease

NCT06604065 ↗

Phase 1 Withdrawn University of Arkansas
RandomizedCrossoverDouble-blindTreatment

Summary

Parkinson's disease is a neuromuscular disease that is relatively common in elderly that has many potentials symptoms, including a variety of physical features that together reduce quality of life. The Study Team have developed a nutritional supplement (AMS2434) based on essential amino acids that targets improving muscle health and brain neurotransmitter balance. This protocol will determine in individuals with PD the effect of AMS2434 on muscle protein synthesis, neurotransmitter production, and mood and cognition.

Timeline

Start
2026-03-09
Primary completion
2026-03-09
Completion
2026-03-09

Outcome

Outcome not reported

Stopped (Business): “project not funded”

Drugs

EvaluationDrugModalityDoseRoute
Subject AMS2434 Other / unclassified 10 g Oral

Indications